-

Fluor Completes Bayer’s First Global Cell Therapy Launch Facility in Berkeley, California

Second new facility built by Fluor on Bayer’s Biotech campus in Berkeley

IRVING, Texas--(BUSINESS WIRE)--Fluor Corporation (NYSE: FLR) announced today that it has completed construction of Bayer’s first global Cell Therapy Launch Facility in Berkeley, California. Completion was celebrated October 10, 2023, at the new facility with local officials, dignitaries, Bayer employees and clients.

Fluor completes Bayer’s first global Cell Therapy Launch Facility in Berkeley, California

Share

“Fluor’s innovative plant layout and modularized construction approach allowed this facility to be built safely and with capital efficiency,” said Richard Meserole, president of Fluor’s Advanced Technologies & Life Sciences business line. “The project was phased to allow start-up activities to commence as needed to support production timeline.”

The new state-of-the-art biopharmaceutical development and manufacturing facility will be used to produce cell therapies for neurological degenerative disorders, cardiovascular disease and other unmet medical needs.

Fluor’s scope of work included the engineering, procurement, construction management, commissioning, qualification and validation for the facility.

Fluor also completed construction of Bayer’s state-of-the-art Single Use Technology biopharmaceutical manufacturing Cell Culture Technology Center (CCTC) in 2021. The CCTC supports Bayer’s teams producing multiple biologic therapies.

About Fluor Corporation

Fluor Corporation (NYSE: FLR) is building a better world by applying world-class expertise to solve its clients’ greatest challenges. Fluor’s 40,000 employees provide professional and technical solutions that deliver safe, well-executed, capital-efficient projects to clients around the world. Fluor had revenue of $13.7 billion in 2022 and is ranked 303 among the Fortune 500 companies. With headquarters in Irving, Texas, Fluor has provided engineering, procurement and construction services for more than 110 years. For more information, please visit www.fluor.com or follow Fluor on Twitter, LinkedIn, Facebook and YouTube.

#ATLS

Contacts

Brett Turner
Media Relations
864.281.6976

Jason Landkamer
Investor Relations
469.398.7222

Fluor Corporation

NYSE:FLR

Release Summary
Fluor Completes Bayer’s First Global Cell Therapy Launch Facility in Berkeley, California
Release Versions

Contacts

Brett Turner
Media Relations
864.281.6976

Jason Landkamer
Investor Relations
469.398.7222

Social Media Profiles
More News From Fluor Corporation

Fluor Receives $1.35 Billion for 71 Million NuScale Shares; Launches Trading Program for Remaining 40 Million Shares

IRVING, Texas--(BUSINESS WIRE)--FLUOR RECEIVES $1.35 BILLION FOR 71 MILLION NUSCALE SHARES; LAUNCHES TRADING PROGRAM FOR REMAINING 40 MILLION SHARES...

Fluor Reports Fourth Quarter and Full Year 2025 Results

IRVING, Texas--(BUSINESS WIRE)--Fluor Corporation (NYSE: FLR) announced financial results for its year ended December 31, 2025. “Our growing confidence in capturing significant EPC awards in 2026 and into 2027 is supported by an improving capital spending environment and increasing client commitments,” said Jim Breuer, chief executive officer of Fluor. “Furthermore, I am pleased that the monetization of our NuScale investment is progressing well and that we are returning significant value to ou...

Fluor Selected as Engineering, Procurement and Construction Partner for Expansion of Centrus’ Uranium Enrichment Plant in Ohio

IRVING, Texas--(BUSINESS WIRE)--Fluor Selected as Engineering, Procurement and Construction Partner for Expansion of Centrus’ Uranium Enrichment Plant in Ohio...
Back to Newsroom